OPRX
Get informed when a big investor buys or sells
+ FollowOvervalued by 19.1% based on the discounted cash flow analysis.
| Market cap | $144.68 Million |
|---|---|
| Enterprise Value | $140.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.28 |
| Beta | 1.05 |
| Outstanding Shares | 18,785,596 |
| P/E Ratio | 31.65 |
|---|---|
| PEG | -21.69 |
| Price to Sales | 1.65 |
| Price to Book Ratio | 1.37 |
| Enterprise Value to Revenue | 1.43 |
| Enterprise Value to EBIT | 126.94 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.15 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1410▲ 67.97% |
|---|---|
| Total Calls | 61,700▼ 41.07% |
| Total Puts | 70,400▲ 45.76% |
Holdings and activity of institutional investors.
| Ownership % | 59.75%▼ 13.25% |
|---|---|
| Total Invested | $64.12M▼ 25.26% |
| Investors Holding | 116▼ 16.00% |
No data
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary ne...